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Summary 
Background Young people with psychosis are at high risk of developing cardiometabolic disorders; however, there is 
no suitable cardiometabolic risk prediction algorithm for this group. We aimed to develop and externally validate a 
cardiometabolic risk prediction algorithm for young people with psychosis.
Methods We developed the Psychosis Metabolic Risk Calculator (PsyMetRiC) to predict up to 6-year risk of incident 
metabolic syndrome in young people (aged 16–35 years) with psychosis from commonly recorded information at 
baseline. We developed two PsyMetRiC versions using the forced entry method: a full model (including age, sex, 
ethnicity, body-mass index, smoking status, prescription of a metabolically active antipsychotic medication, HDL 
concentration, and triglyceride concentration) and a partial model excluding biochemical results. PsyMetRiC was 
developed using data from two UK psychosis early intervention services (Jan 1, 2013, to Nov 4, 2020) and externally 
validated in another UK early intervention service (Jan 1, 2012, to June 3, 2020). A sensitivity analysis was done in UK 
birth cohort participants (aged 18 years) who were at risk of developing psychosis. Algorithm performance was 
assessed primarily via discrimination (C statistic) and calibration (calibration plots). We did a decision curve analysis 
and produced an online data-visualisation app.
Findings 651 patients were included in the development samples, 510 in the validation sample, and 505 in the 
sensitivity analysis sample. PsyMetRiC performed well at internal (full model: C 0·80, 95% CI 0·74–0·86; partial 
model: 0·79, 0·73–0·84) and external validation (full model: 0·75, 0·69–0·80; and partial model: 0·74, 0·67–0·79). 
Calibration of the full model was good, but there was evidence of slight miscalibration of the partial model. At a cutoff 
score of 0·18, in the full model PsyMetRiC improved net benefit by 7·95% (sensitivity 75%, 95% CI 66–82; 
specificity 74%, 71–78), equivalent to detecting an additional 47% of metabolic syndrome cases.
Interpretation We have developed an age-appropriate algorithm to predict the risk of incident metabolic syndrome, a 
precursor of cardiometabolic morbidity and mortality, in young people with psychosis. PsyMetRiC has the potential 
to become a valuable resource for early intervention service clinicians and could enable personalised, informed 
health-care decisions regarding choice of antipsychotic medication and lifestyle interventions.
Funding National Institute for Health Research and Wellcome Trust.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction 
People with psychotic disorders such as schizophrenia 
have a life expectancy shortened by 10–15 years compared 
with the general population,1 predominantly owing to a 
higher prevalence of physical conditions such as 
type 2 diabetes, obesity, and cardiovascular disease 
(CVD).2 These comorbidities lead to a reduced quality of 
life and substantial health economic burden3 and usually 
develop early in the course of the psychotic disorder. For 
example, insulin resistance and dyslipidaemia are 
detectable from the onset of psychosis in adults in the 
second or third decades of life,4,5 probably due to a 
combination of genetic, lifestyle, and other environmental 
influences.6 Since some treatments for psychosis can 
exacerbate cardio metabolic risk (eg, certain anti psychotic 
medications), identification of young adults at the highest 
risk of adverse cardiometabolic outcomes as soon as 
possible after diagnosis of a psychotic disorder is crucial, 
so that interventions can be tailored to reduce the risk of 
longer-term cardiovascular mor bidity and mortality.
Prognostic risk prediction algorithms are a valuable 
means to encourage personalised, informed health-care 
decisions. In the general population, cardiometabolic 
risk prediction algorithms such as QRISK37 are 
commonly used to predict CVD risk from baseline 
demographic, lifestyle, and clinical information, to 
identify higher-risk individuals for tailored interventions. 
A recent systematic review8 explored the suitability of 
existing cardiometabolic risk prediction algorithms for 
young people with psychosis. However, all algorithms 
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were developed in samples of adults with a mean age 
across included studies of 50·5 years, and no studies 
included participants younger than 35 years. Most 
included studies did not include relevant predictors such 
as antipsychotic medication, so the authors of the review 
concluded that none are likely to be suitable for young 
people with psychosis.8 Furthermore, an accompanying 
exploratory analysis found that existing algorithms 
significantly underpredict cardiometabolic risk in young 
people with or at risk of developing psychosis.8
Therefore, following TRIPOD reporting guidelines9 
(appendix p 19), we developed and externally validated 
the Psychosis Metabolic Risk Calculator (PsyMetRiC) to 
predict up to 6-year risk of metabolic syndrome, an age-
appropriate precursor of CVD and early mortality, in 
young people with psychosis. We prioritised clinical 
usefulness and patient acceptability via input from a 
young person’s advisory group, and by developing 




We developed PsyMetRiC using pooled retrospective 
data from patients aged 16–35 years enrolled in 
the Birmingham psychosis early intervention service 
(EIS; sample frame n=391) or Cambridgeshire and 
Peterborough Assessing, Managing and Enhancing 
Outcomes (CAMEO) EIS (sample frame n=1113). 
Anonymised data from the Birmingham psychosis EIS 
were collected between Jan 1, 2014, and Dec 31, 2018, as 
part of the National Clinical Audit of Psychosis Quality 
Improvement programme, and were enhanced locally 
with medication data conforming to the Health Research 
Authority definition of service evaluation, which were 
confirmed by Birmingham Women’s and Children’s 
Hospital National Health Service (NHS) Foundation 
Trust. CAMEO data were identified by anonymously 
searching for EIS patients enrolled between Jan 1, 2013, 
and Nov 4, 2020, using the Clinical Records Anonymisation 
and Text Extraction (CRATE) tool10 (NHS National 
Research Ethics Service references 12/EE/0407 and 
17/EE/0442). Predictors were assessed at the closest point 
(within 100 days) to EIS enrolment, and outcomes were 
assessed up to 6 years later. We excluded patients who had 
less than 1 year of follow-up, had the outcome at baseline, 
or had missing data on all predictor or outcome variables.
To externally validate PsyMetRiC, we used the Clinical 
Records Interactive Search (CRIS) resource to capture 
anonymised data from South London and Maudsley 
NHS Foundation Trust (SLaM) EIS (National Institute 
for Health Research [NIHR] Biomedical Research 
Centre [BRC] CRIS Oversight Committee reference 
20-005). Our sample frame included 2985 EIS patients 
aged 16–35 years enrolled between Jan 1, 2012, and 
June 3, 2020. Patients were excluded and predictors and 
outcomes were assessed in the same manner as for the 
development set.
In a sensitivity analysis, we examined the performance 
of PsyMetRiC in young adults who had or were at risk of 
See Online for appendix
Research in context
Evidence before this study
Cardiometabolic risk prediction algorithms are commonly used in 
the general population as tools to encourage informed, 
personalised treatment decisions with the aim of primary 
prevention of longer-term cardiometabolic outcomes. In a recent 
systematic review of cardiometabolic risk prediction algorithms 
developed either for general or psychiatric populations, we 
searched Embase (1947 to Dec 1, 2019), Ovid MEDLINE 
(1946 to Dec 1, 2019), PsychINFO (1806 to Dec 1, 2019), 
Web of Science (from inception to Dec 1, 2019), and the first 
20 pages of Google Scholar (to Dec 1, 2019). Search terms 
related to cardiometabolic (metabolism, metabolic, diabetes 
mellitus, cardiovascular disease, obesity, cardiometabolic); 
risk prediction (risk assessment, risk, outcome assessment, 
prediction, prognosis); and algorithm (calculator, computers, 
algorithms, software, tool) were included. Over 100 studies 
were included in the review. Yet, few were validated externally, 
only one was developed in a sample of people with mental 
illness, none were done in young populations, most were rated 
as being at high risk of bias, and most did not include relevant 
predictors such as antipsychotic medication. Additionally, 
existing algorithms substantially underpredict cardiometabolic 
risk in young people with or at risk of developing psychosis. 
Therefore, existing algorithms are unlikely to be suitable for 
young people with psychosis.
Added value of this study
We have developed and externally validated, to our knowledge, 
the first clinically useful and age-appropriate cardiometabolic risk 
prediction algorithm tailored for young people with psychosis—
the Psychosis Metabolic Risk Calculator (PsyMetRiC)—using 
patient data from three geographically distinct UK National 
Health Service psychosis early intervention services. PsyMetRiC 
can reliably predict the risk of incident metabolic syndrome in 
young people with psychosis and young people who are at risk of 
developing psychosis.
Implications of all the available evidence
Whereas established risk prediction algorithms are suitable for 
use in older general population samples, with PsyMetRiC we are 
able to extend cardiometabolic risk prediction to young people 
with psychosis, a group who are at significantly higher 
cardiometabolic risk than the general population. Our findings 
can pave the way for a future clinical tool to encourage 
personalised treatment decisions with the aim of improving the 
long-term physical health of young people with psychosis.
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developing psychosis from the Avon Longitudinal Study 
of Parents and Children (ALSPAC) birth cohort 
(appendix p 1).11 Our sample frame included participants 
identified as having experienced definite psychotic 
symp toms at either 18 years or 24 years, assessed via the 
semi-structured Psychosis-Like Symptom Interview 
(appendix p 1). Predictors were assessed at age 18 years, 
and the outcome was assessed at age 24 years. We 
excluded participants as described for the development 
set.
The ALSPAC Ethics and Law Committee and local 
research ethics committees provided ethical approval. 
Informed consent was obtained from patients following 
the recommendations of the ALSPAC Ethics and Law 
Committee at the time the data were collected. 
Outcomes 
We used the harmonised definition12 of the metabolic 
syndrome as a binary outcome, which was at least 
three from the following list: ethnicity-specific waist cir-
cumference of at least 94 cm in males and at least 80 cm 
in females for white people, at least 90 cm in males and 
at least 80 cm in females for other ethnic groups, or 
body-mass index (BMI) greater than 29·9 kg/m²; 
triglyceride concentrations at least 1·70 mmol/L; HDL 
concentration less than 1·03 mmol/L in males or less 
than 1·29 mmol/L in females; systolic blood pressure 
greater than 130 mm Hg; or fasting plasma glucose 
greater than 5·60 mmol/L. 
Predictor variables
Predictors were included based on a balance of clinical 
knowledge, past research, likely clinical usefulness, and 
patient acceptability after discussion of the work with 
the McPin Foundation Young Persons Advisory Group 
(YPAG), a group of volunteers aged younger than 
24 years with personal experience of mental health 
difficulties (appendix p 10). The full model comprised 
age (continuous; years), ethnicity (categorical; white 
European or not recorded [reference], Black or African-
Caribbean, Asian, or other), sex (female or male), BMI 
(continuous; kg/ m²), current smoking status (binary; at 
least one cigarette on average daily), prescription of a 
metabolically active antipsychotic drug (binary; based on 
relative cardiometabolic risk; appendix p 11), HDL 
concentration (continuous; mmol/L), and triglyceride 
concentration (continuous; mmol/L). A partial model, 
without HDL and triglyceride concen trations, was dev-
eloped to cover eventualities where biochemical results 
are not available (appendix pp 5–8).
Statistical analysis
We developed PsyMetRiC using the forced entry method, 
after ruling out predictor multi-collinearity, to minimise 
risk of overfitting and as recommended for smaller 
datasets.13 We did a formal sample size calculation.14 
Briefly, the sample size required was estimated from the 
estimated outcome prevalence, the a priori estimated R² 
of the model, and the estimated required model 
shrinkage. For the full model, the minimum sample 
required was 494, and for the partial model it was 
394 (appendix p 2).14 We did not consider non-linear 
terms or interactions to reduce risk of overfitting. We 
used multiple imputation using chained equations for 
missing data and we pooled estimates using Rubin’s 
rules (appendix p 3). An initial internal validation step 
(500 bootstraps) was done, and coefficients were shrunk 
for optimism using the pooled corrected C slope as a 
shrinkage factor. After this step, predictive performance 
was assessed (see later).
The algorithms were applied to the external validation 
sample. The distribution of predicted outcome prob-
abilities was inspected using histograms. Algorithm 
performance was primarily assessed with measures of 
discrimination (C statistic) and calibration (calibration 
plots; appendix p 4). We also recorded Nagelkerke-Cox-
Snell-Maddala-Magee R² index, the calibration intercept 
(ideally close to 0), C slope (ideally close to 1), and the 
Brier score, which is an overall measure of algorithm 
performance (ideally close to 0, with scores >0·25 
generally indicating a poor model).
Decision curve analysis15 was used to assess the clinical 
usefulness of PsyMetRiC by estimating net benefit. Net 
benefit is a metric of true positives minus false positives, 
and is calculated as
where w is the outcome odds at a given risk threshold.16 
The risk threshold is the amount of tolerable risk before 
an intervention is deemed necessary. Net benefit 
incorporates the consequences of the decisions made 
on the basis of an algorithm, and is therefore preferable 
to related measures such as sensitivity and specificity 
alone.16 We also reported the standardised net benefit 
(net benefit/outcome prev alence) and related metrics 
(sensitivity and specificity). In decision curve analysis, 
consideration only of the range of risk thresholds that 
may reasonably be considered in clinical practice is 
customary. Our upper bound of 0·35 represents a 
greater than one in three chance of developing 
metabolic syndrome should nothing change, and it is 
unlikely that risk thresholds greater than this should be 
tolerated. We drew a decision curve plot to visualise the 
net benefit of both PsyMetRiC versions over varying 
risk thresholds compared with intervening in all 
patients or intervening in no-one. Net harm (ie, more 
false positives than true positives exposed to an 
intervention at a selected risk threshold) is indicated 
when a proposed intervention is plotted at y<0. Classical 
decision theory proposes that at a chosen risk threshold, 
the choice with the greatest net benefit should be 
preferred.16
sensitivity × prevalence – (1 – specificity) 
× (1 – prevalence) × w
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Visual representation of PsyMetRiC
We have provided two simulated case histories applying 
PsyMetRiC algorithms. Additionally, we developed an 
online data-visualisation app using shiny for R, which 
allows an interactive exploration of the effect of 
modifiable and non-modifiable risk factors and their 
combinations on cardiometabolic risk in young people 
with psychosis according to their PsyMetRiC score.
Role of the funding source 
The funders of the study had no role in study design, 
data collection, data analysis, data inter pretation, or 
writing of the report. 
Results 
Data from 651 patients were included in the pooled 
development sample: 352 from the Birmingham EIS and 
299 from CAMEO (table 1). After 500 bootstraps, the 








SLaM EIS external 
validation sample 
(n=510)




Age, years 23·76 (4·90) 25·42 (4·77) 24·52 (4·91) 24·45 (4·75) 17·81 (0·43)
Ethnicity
White European or not 
recorded
111 (32%) 250 (84%) 361 (55%) 154 (30%) 494 (98%)
Black or African-Caribbean 94 (27%) 15 (5%) 109 (17%) 250 (49%) <5 (<1%)*
Asian or other 147 (42%) 34 (11%) 181 (28%) 106 (21%) <5 (<1%)*
Sex
Male 232 (66%) 208 (70%) 440 (68%) 351 (69%) 184 (36%)
Female 120 (34%) 91 (30%) 211 (32%) 159 (31%) 321 (64%)
HDL concentration, mmol/L 1·76 (0·35) 2·08 (0·49) 1·88 (0·57) 1·57 (0·37) 1·21 (0·31)
Triglycerides concentration, 
mmol/L
1·46 (1·18) 1·30 (0·89) 1·39 (1·06) 1·23 (0·71) 1·06 (0·77)
BMI, kg/m2 22·06 (5·13) 24·01 (5·73) 23·63 (5·43) 22·96 (6·94) 23·22 (3·55)
FPG, mmol/L 5·20 (1·02) 5·17 (1·45) 5·19 (1·28) 5·03 (1·10) 5·31 (0·49)
Systolic BP, mm Hg 121·18 (11·04) 119·88 (12·25) 120·65 (11·68) 119·96 (13·70) 115·10 (11·88)
Metabolically active 
antipsychotics†
239 (68%) 216 (72%) 455 (70%) 472 (93%) 58 (11%)
Current smoker 182 (52%) 133 (44%) 315 (48%) 469 (92%)‡ 286 (57%)
Follow-up, years 2·44 (1·54) 1·43 (1·03) 1·86 (1·32) 2·73 (1·76) 5·18 (0·39)
Time of predictor assessment 
from EIS enrolment, days
23·55 (25·44) 21·93 (29·84) 16·71 (26·38) 3·05 (36·01) §
Metabolic syndrome at 
baseline¶
31/383 (8%) 18/317 (6%) 49/700 (7%) 30/540 (6%) 22/527 (4%)
Metabolic syndrome at 
follow-up
74 (21%) 35 (12%) 109 (17%) 86 (17%) 76 (15%)
Data are mean (SD), number (%), or n/N (%). Some percentags do not add up to 100 because of rounding. ALSPAC=Avon Longitudinal Study of Parents and Children. 
BMI=body-mass index. BP=blood pressure. CAMEO=Cambridgeshire and Peterborough Assessing, Managing and Enhancing Outcomes. EIS=early intervention service. 
FPG=fasting plasma glucose. SLaM=South London and Maudsley NHS Foundation Trust. *Reported as <5 owing to ALSPAC reporting guidelines. †Listed in the appendix 
(p 11). ‡Smoking status was derived using the CRIS-IE-Smoking application using natural language processing software to extract ever smoking status information from 
open-text fields (appendix p 6). §Health record and service use data are not available in ALSPAC. ¶N numbers are the sample size before excluding cases with metabolic 
syndrome at baseline. 
Table 1: Demographics and clinical characteristics of patients in the algorithm development and internal and external validation sets
Full model Partial model
Intercept –6·439813 –6·973829
Age, years 0·006233226 0·00633115
Black or African-Caribbean ethnicity 0·004258861 0·07548129
Asian or other ethnicity 0·211217746 0·29285950
Male sex 0·222300765 0·31460036
Body-mass index, kg/m2 0·141186241 0·16912161
Current smoker 0·153691193 0·24751854
Prescribed a metabolically active 
antipsychotic
0·497552758 0·60013558
HDL, mmol/L –0·399013329 *
Triglycerides, mmol/L 0·343528440 *
*Variable not included in model.
Table 2: Final coefficients for the Psychosis Metabolic Risk Calculator 
after shrinkage for optimism
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and 0·93 for the partial model; these values were used as 
shrinkage factors. Final PsyMetRiC coefficients are 
presented in table 2. Histograms showing the distribution 
of predicted outcome probabilities are provided in the 
appendix (p 14).
At internal validation, the pooled performance 
statistics for the full model were C 0·80 (95% CI 
0·74 to 0·86); R² 0·25 (95% CI 0·22 to 0·28); Brier 
score 0·07 (95% CI 0·05 to 0·09); and intercept –0·05 
(95% CI –0·08 to –0·02). For the partial model, these 
statistics were C 0·79 (95% CI 0·73 to 0·84); R² 0·19 
(95% CI 0·14 to 0·24); Brier score 0·10 (95% CI 
0·07 to 0·13); and intercept –0·07 (95% CI 
–0·10 to –0·04). Calibration plots showed good 
agreement between observed and expected risk at most 
predicted probabilities, although in both PsyMetRiC 
versions there was evidence of slight overprediction of 
risk at higher predicted probabilities (appendix p 15).
Our sample frame in the SLaM EIS identified 
2985 patients, 510 of whom were eligible for inclusion in 
the SLaM external validation set; the appendix (p 9) 
provides details of the missing sample analysis. After 
applying PsyMetRiC to the SLaM EIS patient sample, 
performance statistics for the full model were C 0·75 
(95% CI 0·69 to 0·80); R² 0·21 (95% CI 0·18 to 0·25); 
Brier score 0·07 (95% CI 0·04 to 0·10); and intercept –0·05 
(95% CI –0·08 to –0·02). For the partial model, these 
statistics were C 0·74 (95% CI 0·67 to 0·79); R² 0·17 
(95% CI 0·14 to 0·20); Brier score 0·08 (95% CI 
0·05 to 0·11); and intercept –0·07 (95% CI –0·11 to –0·03). 
Calibration plots showed good agreement between 
observed and expected risk in the full model, but in the 
partial model there was evidence of slight miscalibration 
(under prediction of risk at lower predicted probabilities, 
and overprediction of risk at higher predicted prob-
abilities; figure 1). In both models, 95% CIs widened as 
predicted probabilities became more extreme owing to 
lower numbers of participants with more extreme 
predicted probabilities (appendix p 15).
The sample frame for the ALSPAC validation set 
comprised 505 patients. In the ALSPAC sample, 
performance statistics for the full model were C 0·73 
(95% CI 0·66 to 0·79); R² 0·20 (95% CI 0·17 to 0·23); 
Brier score 0·08 (95% CI 0·04 to 0·11); and 
intercept –0·03 (95% CI –0·07 to 0·01). For the partial 
model, these statistics were C 0·71 (95% CI 0·64 to 0·77); 
R² 0·17 (95% CI 0·13 to 0·22); Brier score 0·09 (95% CI 
0·05 to 0·13); and intercept –0·03 (95% CI –0·07 to 0·00). 
The appendix (p 17) shows histograms of predicted 
outcome probabilities. Calibration plots showed good 
agreement between observed and expected risk in the 
full model, albeit with some minor evidence of mis-
calibration (slight underprediction of risk at lower 
predicted probabilities, and overprediction of risk at 
higher predicted prob abilities; appendix p 18). The same 
pattern of slight miscalibration was marginally more 
pronounced in the partial model.
Decision curve analysis suggested that at predicted 
probability cutoffs greater than 0·05, both PsyMetRiC 
algorithms provided greater net benefit than the 
competing extremes of intervening in all patients or in 
none (figure 2). At most risk thresholds greater than 0·05, 
the full model provided slight improvement in net benefit 
compared with the partial model. The appendix (pp 12–13) 
provides numerical decision curve analysis results (net 
benefit, standardised net benefit, sensitivity, and spe-
cificity) across a range of reasonable risk thresholds. For 
example, if an inter vention were considered necessary 
above a risk score of 0·18, the full model would provide a 
net benefit of 7·95% (95% CI 5·37–10·82), with a 
sensitivity of 75% (95% CI 66–82) and specificity of 
74% (71–78), meaning that an additional 47% of metabolic 
Figure 1: Calibration plots for external validation of PsyMetRiC algorithms in 
an early intervention service patient sample
Calibration plots are shown for the PsyMetRiC full model (A) and partial model 
(B). Calibration plots illustrate agreement between observed risk (y axis) and 
predicted risk (x axis). Perfect agreement would trace the red line. Algorithm 
calibration is shown by the dashed line. Triangles denote grouped observations 
for participants at deciles of predicted risk, with 95% CIs indicated by the 
vertical black lines. Axes range between 0 and 0·8 since very few individuals 
received predicted probabilities greater than 0·8. PsyMetRiC=Psychosis 
Metabolic Risk Calculator.
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syndrome cases could be prevented (standardised net 
benefit). At the same risk threshold, the partial model 
would provide a net benefit of 7·74% (95% CI 
4·79–10·36), with a sensitivity of 75% (95% CI 65–81) 
and specificity of 74% (70–77), meaning that an additional 
46% of metabolic syndrome cases could be prevented 
(standardised net benefit). For both models, these data 
equate to around an additional eight cases of metabolic 
syndrome that could be pre vented per 100 individuals, 
without any increase in false positives.
Figure 3 shows decision trees outlining two simulated 
case scenarios to visualise the effect of modifiable and 
non-modifiable risk factors in young people with 
psychosis, as calculated from PsyMetRiC full and partial 
models. We have developed an online data visualisation 
app for both PsyMetRiC versions, which allows the user 
to interactively explore the effect of modifiable and 
non-modifiable risk factors and their combinations on 
cardiometabolic risk in young people with psychosis, 
based on PsyMetRiC scores.
Discussion
We have developed and externally validated PsyMetRiC, 
which is to our knowledge the first cardiometabolic risk 
prediction algorithm tailored specifically for young 
people with psychosis. PsyMetRiC can predict up to 
6-year risk of incident metabolic syndrome from 
commonly recorded clinical information, highlighting 
modifiable risk factors that could be addressed to reduce 
risk. Metabolic syndrome is a precursor to CVD and early 
mortality,18 and is a suitable outcome for younger 
populations, since it occurs more commonly in younger 
adults than do more distal cardiovascular endpoints such 
as CVD. The external validation of both PsyMetRiC 
versions was good, with C statistics greater than 0·70. 
Calibration of the full model was good, but there was 
evidence of slight miscalibration of the partial model. 
Therefore, the partial model in particular may benefit 
from recalibration in larger samples. Both PsyMetRiC 
versions displayed greater net benefit than alternative 
strategies across a range of feasible risk thresholds, 
although at most risk thresholds our results show that 
the full model should be used preferentially.
Our data visualisations help to illustrate three things: 
first, antipsychotic medication choice imparts a sub-
stantial influence on cardiometabolic risk; second, 
addressing lifestyle factors can effectively reduce 
cardiometabolic risk even in the presence of anti-
psychotic medication; and third, advancing age in 
young adults does not influence cardiometabolic risk 
substantially relative to other risk factors. Although 
PsyMetRiC will benefit from future validation in larger 
samples, it has the potential to become a valuable 
resource to promote better management of physical 
health in young people with psychosis—eg, by 
highlighting modifiable risk factors and encouraging 
clinicians to make more personalised, informed 
decisions, such as with the choice of antipsychotic 
medication or lifestyle inter ventions, or both.
Ethnicity, smoking, and BMI are among the most 
commonly included predictors in existing algorithms8 
and are well known contributors to cardiometabolic 
risk,19 so we included them in PsyMetRiC. Sex is also 
frequently considered in existing algorithms,8 and we 
included it in PsyMetRiC. We found that male sex was a 
risk factor for incident metabolic syndrome, which aligns 
with meta-analytic reports that male sex is a risk factor 
for antipsychotic-induced metabolic dysfunction.19 Our 
available sample size was too small to be able to consider 
separate versions of PsyMetRiC for males and females. 
If larger samples become available in the future, 
sex-stratified versions could be considered, since existing 
algorithms developed for the general population com-
monly take this step.8
Age is frequently included in existing algorithms,8 and 
we included it in PsyMetRiC. However, existing cardio-
metabolic risk prediction algorithms, which were 
developed for older adults, weighted age to a greater extent 
than other predictors.8 This is probably because most 
cardiometabolic risk factors contribute cumulative risk 
over time;20 thus, age becomes increasingly important as 
one gets older. A recent exploratory analysis8 that examined 
the predictive performance of the existing general 
population cardio metabolic risk prediction algorithms, 
including QRISK37 and PRIMROSE,21 in young people 
who were at risk of developing psychosis found that each 
significantly underpredicted risk in the younger 
population, possibly owing to the way existing algorithms 
have modelled age. For example, in PsyMetRiC, age is 
weighted to a much lesser extent than other predictors, 
and we achieved favourable calibration in younger 
populations. Although QRISK37 and PRIMROSE21 are 
good examples of well designed algorithms from large 
Figure 2: Decision curve analysis plot for PsyMetRiC full and partial models
The plot reports net benefit (y axis) of PsyMetRiC full and partial models across a 
range of risk thresholds (x axis) compared with intervening in all patients or 
intervening in no patients. PsyMetRiC=Psychosis Metabolic Risk Calculator.





















www.thelancet.com/psychiatry   Published online June 1, 2021   https://doi.org/10.1016/S2215-0366(21)00114-0 7
samples, our results suggest that PsyMetRiC is more 
appropriate for young people with psychosis.
Blood-based predictors, such as HDL and triglyceride 
concentrations, feature relatively infrequently in cardio-
metabolic risk prediction algorithms.8 Meta-analytic 
evidence suggests abnormal triglyceride and HDL 
concentrations are detectable at first-episode psychosis,22 
and a raised triglyceride:HDL ratio is a hallmark of 
insulin resistance,23 which is also associated with 
first-episode psychosis.4 Abnormal HDL and triglyceride 
concentrations are associated longitudinally with cardio-
metabolic outcomes.24 Guideline recommendations 
encourage blood-based monitoring both before and after 
antipsychotic exposure,25 and so such data should be 
available. We found that the inclusion of blood-based 
predictors improved all predictive performance metrics. 
However, blood-based monitoring might not always be 
possible, and we found that the partial model still 
provided reliable performance estimates, although it 
would benefit from recalibration.
Antipsychotic medication is an important contributor 
to cardiometabolic risk in young people with psychosis, 
yet has rarely been included in existing algorithms. 
Some recent algorithms have included anti psychotics 
as predictors, grouped according to the traditional 
distinctions of typical and atypical or first and 
second generation.8 However, the differential cardio- 
 metabolic effects of antipsychotics do not abide by these 
distinctions. Therefore, we instead modelled anti-
psychotics based on previous research (appendix p 11).
Figure 3: Simulated case scenarios to visualise the effect of modifiable and non-modifiable risk factors on cardiometabolic risk in young people with psychosis as calculated from PsyMetRiC 
full and partial models
Case scenarios are shown for the PsyMetRiC full model (A) and partial model (B). PsyMetRiC scores are presented as predicted probabilities, which can be converted to percentage chance of incident 
metabolic syndrome by multiplying by 100. BMI=body-mass index. EIS=early intervention service. NHS=National Health Service. PsyMetRiC=Psychosis Metabolic Risk Calculator. *A raised 
triglyceride:HDL ratio is indicative of insulin resistance.17 
A 24-year-old south Asian man is admitted to a psychiatric inpatient unit in the UK and diagnosed
with psychosis. His BMI is toward the upper limit of the recommended range (24·7 kg/m²). He does
not smoke. His blood test results for cholesterol are abnormal and suggest the possibility of insulin
resistance* (triglycerides 2·51 mmol/L; HDL 1·03 mmol/L)
Initial PsyMetRiC score 0·13
New PsyMetRiC score 0·13
No change in risk of metabolic syndrome
In time, he recovers from the acute psychotic episode, but shows residual symptoms and so opts to
remain on antipsychotic medication. He also accepts referral to a dietitian to address his 
cholesterol levels. 1 year later (age 25 years), improvement is reported on a repeat blood test 
(triglycerides 1·54 mmol/L; HDL 1·33 mmol/L) and his BMI has decreased to 23·3 kg/m². Owing to 
residual symptoms of psychosis, his doctor talks with him about a possible change in medication
He is commenced on aripiprazole
New PsyMetRiC score 0·19
46% increase in risk of metabolic syndrome
He is commenced on olanzapine
A
New PsyMetRiC score 0·07
46% decrease in risk of metabolic syndrome
He continues on aripiprazole
New PsyMetRiC score 0·11
15% decrease in risk of metabolic syndrome
He switches to olanzapine
A 27-year-old white European woman is diagnosed with psychosis in the community and enrolled
in the local NHS EIS. She accepts basic physical assessment only (BMI 26·2 kg/m2, in the overweight
range). She smokes 15 cigarettes per day
Initial PsyMetRiC score 0·11
She is commenced on risperidone
New PsyMetRiC score 0·20
82% increase in risk of metabolic syndrome
After she begins to recover from her psychotic symptoms, she is offered and commits to smoking
cessation therapy and is successful in her efforts. She also talks to her doctor about a change in
medication due to mild adverse effects
New PsyMetRiC score 0·08
60% decrease in risk of metabolic syndrome
With some friends, she also joins a local sports club, and over the course of 1 year, her BMI has
decreased to 24·3 kg/m²
She switches to amisulpride
New PsyMetRiC score 0·16
20% decrease in risk of metabolic syndrome
She continues on risperidone
B
New PsyMetRiC score 0·06
25% decrease in risk of metabolic syndrome
She continues on amisulpride
New PsyMetRiC score 0·12
25% decrease in risk of metabolic syndrome
She continues on risperidone
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PsyMetRiC cannot yet be recommended for clinical 
use and requires prospective validation in larger samples, 
health technology assessment, and regulatory approval. 
However, in the future, PsyMetRiC could become a 
useful resource for the improved management of 
physical health in young people with psychosis. For 
example, in the presence of a very low PsyMetRiC risk 
score, gentle encouragement to maintain good physical 
health might be sufficient. This might include dietary 
advice or promoting daily physical activity and smoking 
cessation, if necessary, or both. There is little harm, yet 
much to gain, in offering gentle encouragement to live a 
healthier life, and such conversations need to become 
part of psychiatric consultation.
Patients and clinicians might prefer to tolerate a 
slightly higher threshold of risk when the proposed 
intervention could be deemed more burdensome or 
might increase the risk of other adverse effects. 
Regarding interventions that might be deemed more 
burdensome, pre scribed lifestyle interventions have 
shown promise in lowering cardiometabolic risk in 
young people with psychosis,17 but regular appointments 
may be difficult to maintain around work or other 
commitments. Regarding interventions that might 
increase the risk of other adverse effects, our results 
show that switching from metabolically active anti-
psychotics, or not prescribing them in the first place, is 
an effective means to reduce cardiometabolic risk. 
However, the risk of psychosis relapse or other adverse 
effects might reasonably be worrisome for patients and 
clinicians alike. Moreover, data from a meta-analysis19 
suggest that metabolically active antipsychotics could be 
associated with greater psychosis treatment response. 
Therefore, antipsychotic selection must strike an 
intricate balance between caring for psychiatric and 
physical health. Finally, trials of treatments such as 
metformin and statins are scarce in young people with 
psychosis, but evidence suggests that such medications 
might benefit both cardiometabolic and psychiatric 
outcomes.26
We have developed, to our knowledge, the first cardio-
metabolic risk prediction algorithm for young people 
with psychosis, harnessing data from three geographically 
distinct patient samples and a population-based cohort. 
PsyMetRiC was developed in consultation with The 
McPin Foundation YPAG to ensure balance between 
clinical practicality and patient acceptability, and we 
received encouraging comments from the YPAG about 
PsyMetRiC (appendix p 10). We developed an online 
interactive app permitting a visualisation of the effect of 
different cardiometabolic risk factors in young people 
with psychosis. We have published our algorithm 
coefficients to encourage future validation and updating. 
We developed two versions of PsyMetRiC to maximise 
clinical utility and both validated well, suggesting that 
PsyMetRiC is likely to be suitable for use in patients 
aged 16–35 years from a UK EIS population, and, from 
the results of our sensitivity analysis, for use in young 
adults at risk of developing psychosis.
Limitations of the study include missing data. We 
excluded participants who had the outcome at baseline, as 
recommended;27 however, since predictors were assessed 
within a short timeframe after EIS enrolment, some 
metabolically sensitive individuals might have been 
excluded from our analysis. We also excluded participants 
with data missing on either all exposure or all outcome 
variables, which might also have introduced selection bias. 
The missing samples were more likely to be older and 
female, and less likely to be prescribed metabolically active 
antipsychotics. These factors might have affected some 
PsyMetRiC predictor coefficients. Nevertheless, we felt this 
exclusion step was more appropriate than imputing 
complete participant data. Multiple imputation can be 
biased when data are missing not at random, although we 
included auxiliary variables to reduce the fraction of 
missing information, limiting the effect of this bias. 
External validation of PsyMetRiC on larger samples 
is required since simulation studies have suggested a 
minimum of 100 outcome events for an accurate validation 
analysis.28 Larger prospectively collected samples in future 
might also allow for updating the algorithm with 
interactions, non-linear terms, sex stratification, and other 
potentially important predictors such as other metabolically 
active medications, physical activity, and diet. Prospectively 
collected data might also predict longer-term risk. The 
samples in our main analysis had outcomes measured up 
to 6 years; however, the mean follow-up time was shorter. 
Although our data-driven classification of metabolically 
active anti psychotics is an advance over existing algorithms, 
the metabolically active nature of different antipsychotics 
lies on a continuum rather than a dichotomy. Larger 
samples might permit the modelling of antipsychotics 
individually. Prescriber bias might have downwardly biased 
the coefficients for anti psychotics, since meta bolically 
active medications might have been withheld from patients 
considered to be at higher cardiometabolic risk.
PsyMetRiC has the potential to become a valuable 
resource for health-care professionals working in EISs 
by aiding the informed choice of antipsychotic 
medication, prescription of cardioprotective drugs, and 
non-pharmacological interventions including lifestyle 
adjustments to prevent the future development of 
cardiometabolic comorbidities and consequent years of 
life lost.
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